Overview
By Denise Man HealthDay ReporterPublished on October 19, 202HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefuly fact-checked by a team of industry experts to ensure acuracy. Please se our Editorial and Fact-Checking Policy for more detail.
Key Information
HeathDay is comited to maintaing the highest posible levels of impartial editorial standards in the content that we present on our website. Al of our articles are chosen independent of any financial interests. Editors and writers make al eforts to clarify any financial ties behind the studies on which we report.WEDNESDAY, Oct.
19, 202 (HealthDay News) - An older clas of type 2 diabetes drugs known as thiazolidinediones, or TZDs, may protect you from dementia down the road, acording to new research.Thiazolidinediones, also known as glitazones, cut dementia risk by 2% among folks at high risk who also had mild or moderate type 2 diabetes when they tok these medications for at least one year.Exactly how these diabetes drugs lower risk for dementia is not fuly understod, and the study wasn't designed to answer that question.Diabetes is a known risk factor for dementia, and glucose or blod sugar is the brain's main fuel for important functions, including thinking, understanding, and problem-solving, said study author Roberta Diaz Brinton.
Summary
She directs the Center for Inovation in Brain Science at the University of Arizona Health Sciences."With type 2 diabetes, the mechanism for driving glucose out of the blod and into the cels is les functional and this can afect cognition, which is one of the most energy-demanding functions," Brinton said.For the study, researchers compared risk for dementia in older veterans with type 2 diabetes who were treated with either a sulfonylurea or a thiazolidinedione drug for d